Predictions

NOAA August 2026 mid-season hurricane outlook update maintains or increases its named storm count forecast above the lower bound of 8 named storms

NOAA current forecast: 8-14 named storms. El Niño developing suppresses activity but Gulf SST elevated. If early season produces 2-3 storms by August, NOAA likely maintains forecast. If El Niño intensifies faster than expected, potential downward revision to 6-10 range. Roughly balanced: below-normal season is the modal outcome but named storm count above 8 lower bound depends on peak-season Atlantic SST and El Niño strength at update time. P=0.53.

FDA will issue 60-day filing acceptance letter for Vertex povetacicept IgAN BLA by June 5, 2026

Vertex completed rolling BLA submission in early April 2026. BTD-granted program. 60-day acceptance clock started ~April 1-5, placing acceptance deadline at ~June 1-5. RTF (refuse-to-file) rate for BTD/rolling programs is 5-10%. Acceptance is essentially FDA confirming the submission is complete and reviewable. RAINIER Phase 3 interim showed 52% UPCR reduction. Cornelius: BLA acceptance with complete submission is >95% base rate. 88% reflects high confidence with small uncertainty about submissi

FDA will accept (no RTF) Vertex povetacicept BLA for IgA nephropathy by June 5 2026

Rolling BLA completed early April 2026 using Priority Review Voucher. BTD granted. 60-day acceptance clock started ~April 1-5. RAINIER Phase 3 interim: 52% UPCR reduction. RTF rate historically 5-10% for rolling BTD programs. Vertex has strong regulatory track record. Cleon calibration note: cap at 80% for high-confidence bucket.

FDA will formally accept Vertex povetacicept BLA for IgA nephropathy (file acceptance letter with PDUFA date) by June 5 2026

Rolling BLA completed early April 2026 via PRV (6-month review). BTD granted. FDA's 60-day acceptance clock started around April 1-5. RTF rate is 5-10% but very low for BTD/rolling BLA programs with pre-submission engagement. RAINIER Phase 3 showed 52% UPCR reduction - robust efficacy signal. Expected PDUFA ~November 2026. Calibration: +17pp from Cleon.

FDA accepts Vertex povetacicept IgA nephropathy BLA for review without Refuse-to-File (RTF) letter by June 5, 2026

BTD granted. Rolling BLA completed early April 2026 using Priority Review Voucher (6-month review). 60-day acceptance clock started ~April 1-5. RTF rate only 5-10% in general; even lower for BTD/rolling programs where agency has been engaged throughout. RAINIER Phase 3 showed 52% UPCR reduction. Calibration +17pp applied to base 0.75; capped at 0.88.

FDA accepts Vertex povetacicept IgAN BLA for review (no Refuse to File) by June 5

Rolling BLA completed early April 2026 using PRV (6-month review). FDA 60-day acceptance clock started ~April 1-5. BTD granted = FDA actively engaged with Vertex data package during rolling review. RTF rate for BTD/rolling programs is 2-5% vs 5-10% baseline. RAINIER interim showed 52% UPCR reduction = strong efficacy signal. Calibration: +17pp applied.

FDA will accept (no RTF) Vertex povetacicept BLA for IgA nephropathy by June 5 2026

Rolling BLA completed early April 2026. BTD granted. RAINIER 52% UPCR reduction. RTF base rate for BTD rolling BLA programs ~5-10%. 60-day acceptance clock started April 1-5 -> decision by June 1-5. High probability of acceptance. Calibration notes: acceptance prediction not approval decision; lower FDA uncertainty applies. P=0.80.

Vertex povetacicept IgAN BLA accepted by FDA by June 5 2026

Rolling BLA completed early April 2026 using Priority Review Voucher (6-month review). BTD granted. FDA 60-day acceptance clock started ~April 1-5, making acceptance date ~June 1-5. RTF (Refuse to File) rate is 5-10% overall but very low for BTD/rolling programs (~2-3%). RAINIER Phase 3 interim showed 52% UPCR reduction. Calibration notes warn FDA deteriorated; accepting that lower RTF base rate for BTD programs justifies 83%.

FDA will NOT issue a Refuse to File (RTF) letter for Vertex povetacicept IgAN BLA; BLA will be accepted for review by June 5 2026

Rolling BLA completed by end of March 2026. BTD granted for IgAN (FDA highly engaged). Priority Review Voucher filed (6-month review, not standard 10-month). RAINIER interim: 49.8% UPCR reduction significant and clinically meaningful. RTF rate for BTD/rolling BLA programs is very low (2-5%). FDA 60-day clock started ~April 1-5. Acceptance letter expected by June 5. Calibration notes: FDA domain severely deteriorated. But BLA acceptance is a lower bar than approval (filing review only). Setting 0

FDA will formally accept Vertex povetacicept BLA by June 5, 2026 (60-day acceptance clock)

Rolling BLA completed early April 2026. BTD granted. 60-day acceptance clock started ~April 1-5, placing acceptance deadline ~June 1-5. RTF rate is 5-10% overall but very low (~2-3%) for BTD programs with rolling BLA. RAINIER Phase 3 showed 52% UPCR reduction. IgAN is a high-priority rare disease indication. FDA acceptance of BTD/rolling BLA programs is nearly routine barring major manufacturing or data deficiency. Calibration adjustment from 88% to 82% per FDA degradation guidance.

FDA will NOT issue a Refuse to File (RTF) decision for Vertex povetacicept IgA nephropathy BLA by June 5 2026 (BLA will be accepted for review)

Povetacicept (BAFF/APRIL inhibitor) RAINIER Phase 3 showed 52% UPCR reduction. BTD granted. Rolling BLA completed early April 2026 using priority review voucher (6-month review). FDA 60-day acceptance clock started ~April 1-5. RTF rate for rolling BLA submissions with BTD is extremely low (5-10% overall for NDAs/BLAs, lower for BTD/priority review completions). Vertex has extensive FDA experience from CF drug approvals. Complete rolling BLA signals comprehensive data package. Story estimate 88%.

FDA accepts Vertex povetacicept BLA for IgA nephropathy and grants Priority Review designation (6-month review) by June 5 2026

Rolling BLA completed early April 2026 using PRV. BTD granted. RAINIER Phase 3 52% UPCR reduction. Priority Review was already secured via PRV (which provides 6-month review vs standard 10-month). Acceptance is near-certain for BTD/rolling BLA programs (~95%). Priority Review is essentially guaranteed by the PRV used. Cornelius: BLA acceptance is near-certainty, PR is tied to PRV. Calibration: 90%+ for acceptance, 82% for the combined conditional. Cap at 0.82 per calibration notes.

FDA accepts (issues 74-day letter without RTF) Vertex povetacicept BLA for IgA nephropathy by June 5, 2026

Rolling BLA completed early April 2026 using Priority Review Voucher. Breakthrough Therapy Designation granted. RAINIER Phase 3 interim showed 52% UPCR reduction. FDA 60-day acceptance clock started ~April 1-5. RTF rate for BTD/rolling programs is very low (2-5%). FDA has strong precedent accepting IgAN BLAs (sparsentan, iptacopan). Apply Cleon FDA penalty: story says 88% → adjusted 80%. FDA acceptance (not approval) is a lower bar than final approval.

FDA will accept Vertex Pharmaceuticals' BLA for povetacicept (IgA nephropathy) with a PDUFA date in Q4 2026 (no Refuse-to-File decision) by June 5, 2026

RAINIER Phase 3 met all primary and secondary endpoints. BTD granted. Rolling BLA completed early April 2026 using Priority Review Voucher (6-month review). FDA 60-day acceptance clock started ~April 1-5. June 5 is exactly 60 days from April 6. RTF rate for BTD programs with rolling BLA is very low (2-5%). Vertex has deep regulatory experience (CFTR franchise, multiple prior approvals). Story probability: 88%. CalNotes: FDA predictions deteriorated - anchor to base rates. RTF base rate for BTD r

NOAA updates August 2026 Atlantic hurricane season outlook maintaining below-normal classification

El Nino strengthening rapidly (spot +1.7C, 63% very strong by winter) is the dominant suppressor of Atlantic activity. NOAA current forecast: 8-14 named storms, below-normal (55% probability). CSU June update downgraded to 11 storms. With El Nino likely strengthening through SON, NOAA August update is very likely to maintain below-normal classification rather than upgrade.

A new named tropical storm or typhoon (distinct from Bavi) will form in the Western Pacific basin before August 10, 2026

All three arms converged at 0.82. 2026 WPac season is running 40% above the long-term average with 9 named storms by late July (Typhoon Bavi No. 9 active at 110kt/910hPa). Historical base rate for at least one new named storm in any 13-day window during peak season in above-average years is 75-85%; favorable SSTs and El Nino eastward track shift maintain formation dynamics. Applied -5.6pp overconfidence correction from calibration notes and 0.85 ceiling for weather formation events.

Strait of Hormuz PortWatch total weekly vessel transit count remains below 100 ships for the entire week of August 3-9, 2026.

Current transits are ~10/day (~70/week), well below the 100/week threshold. P&I insurance withdrawal is structurally binding through August 18, making mass commercial return physically impossible regardless of diplomatic shifts in the 7-day window. Arms (0.91, 0.93, 0.93) agreed that all three constraints — traffic level, insurance floor, and conflict state — must simultaneously fail for breach, which is near-impossible.

FDA will accept Vertex Therapeutics povetacicept BLA for review without Refuse-to-File by June 5, 2026

Rolling BLA completed early April 2026 using Priority Review Voucher (6-month review). Breakthrough Therapy Designation granted. RAINIER Phase 3 interim showed 52% UPCR reduction. 60-day FDA review clock for RTF started approximately April 1-5. RTF rate is generally 5-10% but extremely low for BTD programs with completed rolling submissions. Vertex has strong regulatory track record.

FDA will accept (file) Vertex povetacicept BLA for IgA nephropathy within 60-day window by June 5 2026

Rolling BLA completed early April 2026 using Priority Review Voucher. Breakthrough Therapy Designation granted. RAINIER Phase 3 showed 52% UPCR reduction (clinically meaningful). RTF rate for BTD/rolling programs is very low (5-10%). FDA 60-day clock started ~April 1-5. Cleon +17pp (raw 0.70).

FDA will accept (file) the Vertex povetacicept BLA for IgA nephropathy and send a 60-day letter by June 5, 2026

Rolling BLA completed early April 2026 using PRV (6-month review). BTD granted. FDA 60-day acceptance clock started ~April 1-5. RTF rate for rolling BLA submissions with BTD is 5-10%. RAINIER Phase 3 showed 52% UPCR reduction (strong efficacy). Very unlikely FDA refuses to file. Base 85% acceptance + Calibration +17pp → 88%. PDUFA expected ~November 2026 if accepted.